Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Darunavir is an HIV Protease INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of Antiviral DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
Description | Darunavir is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS. |
In vivo | Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2]. |
Synonyms | TMC114 |
Molecular Weight | 547.66 |
Formula | C27H37N3O7S |
CAS No. | 206361-99-1 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 35 mg/mL (78.14 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Darunavir 206361-99-1 Microbiology/Virology Proteases/Proteasome HIV Protease AID TMC-114 Minimal TMC114 TMC 114 cytotoxicity UIC 94017 Human immunodeficiency virus UIC94017 Inhibitor inhibit HIV UIC-94017 inhibitor